DD148216A5 - Verfahren zur herstellung neuer cyclododecanderivate - Google Patents
Verfahren zur herstellung neuer cyclododecanderivate Download PDFInfo
- Publication number
- DD148216A5 DD148216A5 DD79217646A DD21764679A DD148216A5 DD 148216 A5 DD148216 A5 DD 148216A5 DD 79217646 A DD79217646 A DD 79217646A DD 21764679 A DD21764679 A DD 21764679A DD 148216 A5 DD148216 A5 DD 148216A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- mol
- general formula
- cyclododecane
- group
- atom
- Prior art date
Links
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical class C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 125000001453 quaternary ammonium group Chemical group 0.000 claims abstract description 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000001301 oxygen Substances 0.000 claims abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 239000011593 sulfur Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 20
- -1 alkali metal nitride Chemical class 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract description 33
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 abstract description 13
- 229910000104 sodium hydride Inorganic materials 0.000 abstract description 13
- 239000012312 sodium hydride Substances 0.000 abstract description 13
- SCRFXJBEIINMIC-UHFFFAOYSA-N n-cyclododecylidenehydroxylamine Chemical compound ON=C1CCCCCCCCCCC1 SCRFXJBEIINMIC-UHFFFAOYSA-N 0.000 abstract description 12
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 6
- HJDKXIDZVWPKSY-UHFFFAOYSA-N 3-(cyclododecylideneamino)oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCON=C1CCCCCCCCCCC1 HJDKXIDZVWPKSY-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011541 reaction mixture Substances 0.000 abstract description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000908 ammonium hydroxide Substances 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 101100242909 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) pbpA gene Proteins 0.000 abstract 2
- 101100269618 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) aliA gene Proteins 0.000 abstract 2
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- SXVPOSFURRDKBO-UHFFFAOYSA-N Cyclododecanone Chemical compound O=C1CCCCCCCCCCC1 SXVPOSFURRDKBO-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000008298 dragée Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- YFIASDXULNXOAZ-UHFFFAOYSA-N 2-(cyclododecylideneamino)oxy-n,n-diethylethanamine Chemical compound CCN(CC)CCON=C1CCCCCCCCCCC1 YFIASDXULNXOAZ-UHFFFAOYSA-N 0.000 description 2
- UGXACBBAXFABGT-UHFFFAOYSA-N 3-chloro-n,n,2-trimethylpropan-1-amine Chemical compound ClCC(C)CN(C)C UGXACBBAXFABGT-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229940039750 aconitine Drugs 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- FFGBYFBTNGZKMI-UHFFFAOYSA-N n-(3-morpholin-4-ylpropoxy)cyclododecanimine Chemical compound C1COCCN1CCCON=C1CCCCCCCCCCC1 FFGBYFBTNGZKMI-UHFFFAOYSA-N 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UCKHTPAUJANREL-UHFFFAOYSA-N 1,1-di(propan-2-yl)-2-propoxyhydrazine;dihydrochloride Chemical compound Cl.Cl.CCCONN(C(C)C)C(C)C UCKHTPAUJANREL-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- HKKQSNCJIFHCQD-UHFFFAOYSA-N 1-chloro-4-methylhexane Chemical compound CCC(C)CCCCl HKKQSNCJIFHCQD-UHFFFAOYSA-N 0.000 description 1
- NVGXXXNUGIYECN-UHFFFAOYSA-N 2-(cyclododecylideneamino)oxy-n,n-dimethylethanamine Chemical compound CN(C)CCON=C1CCCCCCCCCCC1 NVGXXXNUGIYECN-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- LUDVXWQMOSWOKZ-UHFFFAOYSA-N 3-(cyclododecylideneamino)oxy-n,n-di(propan-2-yl)propan-1-amine Chemical compound CC(C)N(C(C)C)CCCON=C1CCCCCCCCCCC1 LUDVXWQMOSWOKZ-UHFFFAOYSA-N 0.000 description 1
- SVLPIZNVKGEAET-UHFFFAOYSA-N 3-(cyclododecylideneamino)oxy-n,n-diethyl-2-methylpropan-1-amine Chemical compound CCN(CC)CC(C)CON=C1CCCCCCCCCCC1 SVLPIZNVKGEAET-UHFFFAOYSA-N 0.000 description 1
- RXYQHVMJQFHKDX-UHFFFAOYSA-N 3-chloro-n,n-di(propan-2-yl)propan-1-amine Chemical compound CC(C)N(C(C)C)CCCCl RXYQHVMJQFHKDX-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- NTEIKCIVGUBNAD-UHFFFAOYSA-N Cl.Cl.Cl.C1CNCCN1CCCONCC1=CC=CC=C1 Chemical compound Cl.Cl.Cl.C1CNCCN1CCCONCC1=CC=CC=C1 NTEIKCIVGUBNAD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- MFNBBRSQPZRVAK-UHFFFAOYSA-N [Na].C1(CCCCCCCCCCC1)=NO Chemical compound [Na].C1(CCCCCCCCCCC1)=NO MFNBBRSQPZRVAK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- KPJPHPFMCOKUMW-UHFFFAOYSA-N iodomethane Chemical compound I[CH2] KPJPHPFMCOKUMW-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- DBVADBHSJCWFKI-UHFFFAOYSA-N n-(2-chloroethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)CCCl DBVADBHSJCWFKI-UHFFFAOYSA-N 0.000 description 1
- IRSNFALUAOOYBR-UHFFFAOYSA-N n-[2-(cyclododecylideneamino)oxyethyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)CCON=C1CCCCCCCCCCC1 IRSNFALUAOOYBR-UHFFFAOYSA-N 0.000 description 1
- UCHDCYCNZOUPJQ-UHFFFAOYSA-N n-propoxymorpholin-4-amine;dihydrochloride Chemical compound Cl.Cl.CCCONN1CCOCC1 UCHDCYCNZOUPJQ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UBVSMBHQHHGRSR-UHFFFAOYSA-N o-[2-(dimethylamino)ethyl]hydroxylamine;dihydrochloride Chemical compound Cl.Cl.CN(C)CCON UBVSMBHQHHGRSR-UHFFFAOYSA-N 0.000 description 1
- IWCIDSAYQRVUOI-UHFFFAOYSA-N o-[3-(diethylamino)propyl]hydroxylamine;dihydrochloride Chemical compound Cl.Cl.CCN(CC)CCCON IWCIDSAYQRVUOI-UHFFFAOYSA-N 0.000 description 1
- ICEFYPRSPSDJFD-UHFFFAOYSA-N o-[3-(dimethylamino)propyl]hydroxylamine;dihydrochloride Chemical compound Cl.Cl.CN(C)CCCON ICEFYPRSPSDJFD-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU78EE2614A HU178518B (en) | 1978-12-19 | 1978-12-19 | Process for preparing cyclododekanone oxime ethers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD148216A5 true DD148216A5 (de) | 1981-05-13 |
Family
ID=10995810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD79217646A DD148216A5 (de) | 1978-12-19 | 1979-12-13 | Verfahren zur herstellung neuer cyclododecanderivate |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4285942A (cs) |
| JP (1) | JPS55108847A (cs) |
| AT (1) | AT372079B (cs) |
| AU (1) | AU530721B2 (cs) |
| BE (1) | BE880508A (cs) |
| CA (1) | CA1123852A (cs) |
| CH (1) | CH647755A5 (cs) |
| CS (1) | CS209944B2 (cs) |
| DD (1) | DD148216A5 (cs) |
| DE (1) | DE2951235A1 (cs) |
| DK (1) | DK541079A (cs) |
| ES (1) | ES487090A0 (cs) |
| FI (1) | FI793964A7 (cs) |
| FR (1) | FR2444666A1 (cs) |
| GB (1) | GB2045744B (cs) |
| GR (1) | GR74018B (cs) |
| HU (1) | HU178518B (cs) |
| IL (1) | IL58815A (cs) |
| IT (1) | IT1220957B (cs) |
| NL (1) | NL7909025A (cs) |
| PL (1) | PL120041B1 (cs) |
| SE (1) | SE7910430L (cs) |
| SU (1) | SU833157A3 (cs) |
| YU (2) | YU308479A (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU189226B (en) * | 1983-02-08 | 1986-06-30 | Egyt Gyogyszervegyeszeti Gyar,Hu | Process for producing basic oxime-ethers |
| HU212262B (en) * | 1992-10-30 | 1996-04-29 | Egyt Gyogyszervegyeszeti Gyar | Process to prepare benz /e/ indene derivs. and the pharmaceutical compns. contg. them |
| US5508302A (en) * | 1994-09-28 | 1996-04-16 | American Home Products Corporation | Phospholipase A2 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1733462A (en) * | 1926-09-23 | 1929-10-29 | Winthrop Chem Co Inc | New basic oxime ethers of cyclic compounds |
| US4083978A (en) * | 1976-01-27 | 1978-04-11 | Egyt Gyogyszervegyeszeti Gyar | Oxime ethers |
-
1978
- 1978-12-19 HU HU78EE2614A patent/HU178518B/hu not_active IP Right Cessation
-
1979
- 1979-11-27 IL IL58815A patent/IL58815A/xx unknown
- 1979-12-03 US US06/099,507 patent/US4285942A/en not_active Expired - Lifetime
- 1979-12-03 AT AT0765379A patent/AT372079B/de not_active IP Right Cessation
- 1979-12-03 GR GR60658A patent/GR74018B/el unknown
- 1979-12-07 CS CS798554A patent/CS209944B2/cs unknown
- 1979-12-10 BE BE1/9638A patent/BE880508A/fr not_active IP Right Cessation
- 1979-12-10 FR FR7930183A patent/FR2444666A1/fr active Granted
- 1979-12-13 DD DD79217646A patent/DD148216A5/de unknown
- 1979-12-14 NL NL7909025A patent/NL7909025A/nl not_active Application Discontinuation
- 1979-12-17 YU YU03084/79A patent/YU308479A/xx unknown
- 1979-12-17 IT IT28029/79A patent/IT1220957B/it active
- 1979-12-18 DK DK541079A patent/DK541079A/da not_active Application Discontinuation
- 1979-12-18 FI FI793964A patent/FI793964A7/fi not_active Application Discontinuation
- 1979-12-18 AU AU53967/79A patent/AU530721B2/en not_active Ceased
- 1979-12-18 SU SU792855002A patent/SU833157A3/ru active
- 1979-12-18 SE SE7910430A patent/SE7910430L/xx not_active Application Discontinuation
- 1979-12-18 GB GB7943550A patent/GB2045744B/en not_active Expired
- 1979-12-18 CH CH11197/79A patent/CH647755A5/de not_active IP Right Cessation
- 1979-12-19 JP JP16416379A patent/JPS55108847A/ja active Pending
- 1979-12-19 ES ES487090A patent/ES487090A0/es active Granted
- 1979-12-19 DE DE19792951235 patent/DE2951235A1/de not_active Withdrawn
- 1979-12-19 CA CA342,285A patent/CA1123852A/en not_active Expired
- 1979-12-19 PL PL1979220531A patent/PL120041B1/pl unknown
-
1983
- 1983-04-21 YU YU00912/83A patent/YU91283A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH647755A5 (de) | 1985-02-15 |
| PL220531A1 (cs) | 1980-08-25 |
| AU5396779A (en) | 1980-06-26 |
| AU530721B2 (en) | 1983-07-28 |
| ES8100257A1 (es) | 1980-11-01 |
| DE2951235A1 (de) | 1980-11-06 |
| AT372079B (de) | 1983-08-25 |
| IL58815A (en) | 1984-01-31 |
| BE880508A (fr) | 1980-06-10 |
| FR2444666B1 (cs) | 1982-11-12 |
| ATA765379A (de) | 1983-01-15 |
| CA1123852A (en) | 1982-05-18 |
| IT7928029A0 (it) | 1979-12-17 |
| NL7909025A (nl) | 1980-06-23 |
| GB2045744A (en) | 1980-11-05 |
| IT1220957B (it) | 1990-06-21 |
| YU91283A (en) | 1983-12-31 |
| IL58815A0 (en) | 1980-02-29 |
| PL120041B1 (en) | 1982-02-27 |
| GR74018B (cs) | 1984-06-06 |
| DK541079A (da) | 1980-06-20 |
| CS209944B2 (en) | 1981-12-31 |
| HU178518B (en) | 1982-05-28 |
| US4285942A (en) | 1981-08-25 |
| FR2444666A1 (fr) | 1980-07-18 |
| JPS55108847A (en) | 1980-08-21 |
| FI793964A7 (fi) | 1981-01-01 |
| ES487090A0 (es) | 1980-11-01 |
| SU833157A3 (ru) | 1981-05-23 |
| YU308479A (en) | 1983-12-31 |
| SE7910430L (sv) | 1980-06-20 |
| GB2045744B (en) | 1982-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69621026T2 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
| DE3785507T2 (de) | Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. | |
| CH664567A5 (de) | Aromatische carbonsaeure- und sulfonsaeureester oder -amide. | |
| DE2011806C3 (de) | Tricyclische Verbindungen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| DE3736664A1 (de) | Tetrahydro-furo- und -thieno(2,3-c)pyridine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung | |
| DE19541264A1 (de) | Purin-6-on-derivate | |
| DE69116237T2 (de) | Derivate von Hexahydroazepine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE69216260T2 (de) | Piperidinderivate | |
| DE4430091A1 (de) | Verwendung von N-substituierten Phenothiazinen | |
| DE69329084T2 (de) | Benzoxazepin-Derivate als Cholinesterase-Inhibitoren | |
| DE3500251C2 (de) | Neue 8alpha-Acylaminoergoline | |
| DD300105A5 (de) | Neue R(-)3-Quinuliclidinol - Derivate | |
| DE69819266T2 (de) | Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten | |
| EP0307814B1 (de) | Tetracyclische Chinazolinderivate, Herstellung und Verwendung | |
| DE69014930T2 (de) | Aralkylamin-Verbindungen. | |
| DD148216A5 (de) | Verfahren zur herstellung neuer cyclododecanderivate | |
| EP0389425B1 (de) | Neue Benzothiopyranylamine | |
| DE3228992A1 (de) | Spirothiazolidindion-derivate, herstellung dieser verbindungen und diese enthaltende pharmazeutische praeparate | |
| DE2349493A1 (de) | 2-(2-pyridyl)- omega-phenylalkylamine und verfahren zu ihrer herstellung | |
| DE2550005A1 (de) | Phenylpyridylaminderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
| CH666035A5 (de) | 8-alpha-acylaminoergolene. | |
| DE2442158B2 (de) | Neue substituierte N- [l-(3,4-Methylendioxyphenyl) propyl (2)] -N'-subst Phenylpiperazine | |
| DE4300696A1 (de) | Substituierte N-Aminoalkylmethansulfanilide als Antispasmodika | |
| DE69322218T2 (de) | Heteroarenylpiperazine, Verfahren zu ihrer Herstellung und ihre Anwendung als Medikamente | |
| DE3017560A1 (de) | 9-amino-6,7-dihydro-4h-pyrido eckige klammer auf 1,2-a eckige klammer zu pyrimidin-4-on-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische kompositionen |